Colchicine (colchicine): Uses, Dosage & Side Effects

What it's for (Indications)

Colchicine is clinically indicated for the treatment of acute gout flares, serving as a highly effective anti-inflammatory agent to alleviate the severe pain and inflammation associated with these episodes.
Furthermore, it is widely utilized for the prophylaxis of gout attacks, particularly beneficial during the initiation phase of urate-lowering therapies such as allopurinol or febuxostat, where the mobilization of uric acid crystals can paradoxically trigger flares.
Beyond its application in gout management, colchicine is a cornerstone therapy for Familial Mediterranean Fever (FMF), a genetic autoinflammatory disorder.
In FMF, it is prescribed to prevent recurrent attacks of fever and serositis, and crucially, to prevent the long-term complication of amyloidosis, which can lead to organ damage.
Its anti-inflammatory properties, distinct from NSAIDs, make it valuable in these specific inflammatory conditions by disrupting fundamental cellular processes involved in inflammation.

Dosage Information

Type	Guideline
Standard	The dosing regimen for colchicine varies significantly based on the indication and patient-specific factors, including renal and hepatic function, and potential drug interactions. For acute gout flares, a common initial adult dose is 1.2 mg orally, followed by 0.6 mg one hour later. A maximum of 1.8 mg per single acute gout flare is generally recommended, and treatment should not be re-initiated for at least two weeks. For gout flare prophylaxis, the typical adult dose is 0.6 mg once or twice daily, not exceeding 1.2 mg per day. In Familial Mediterranean Fever (FMF), the adult dosage typically ranges from 1.2 mg to 2.4 mg daily, often divided into two doses, adjusted based on clinical response and tolerability. Dosage adjustments are imperative for patients with renal or hepatic impairment; for instance, significant dose reductions or even avoidance are necessary in severe cases. Similarly, concomitant use with moderate CYP3A4 inhibitors or P-gp inhibitors necessitates dose reduction or interruption of colchicine therapy to mitigate the risk of severe toxicity. Healthcare professionals must meticulously review patient medication lists and organ function before prescribing colchicine.

Type

Guideline

Standard

The dosing regimen for colchicine varies significantly based on the indication and patient-specific factors, including renal and hepatic function, and potential drug interactions. For acute gout flares, a common initial adult dose is 1.2 mg orally, followed by 0.6 mg one hour later. A maximum of 1.8 mg per single acute gout flare is generally recommended, and treatment should not be re-initiated for at least two weeks. For gout flare prophylaxis, the typical adult dose is 0.6 mg once or twice daily, not exceeding 1.2 mg per day. In Familial Mediterranean Fever (FMF), the adult dosage typically ranges from 1.2 mg to 2.4 mg daily, often divided into two doses, adjusted based on clinical response and tolerability. Dosage adjustments are imperative for patients with renal or hepatic impairment; for instance, significant dose reductions or even avoidance are necessary in severe cases. Similarly, concomitant use with moderate CYP3A4 inhibitors or P-gp inhibitors necessitates dose reduction or interruption of colchicine therapy to mitigate the risk of severe toxicity. Healthcare professionals must meticulously review patient medication lists and organ function before prescribing colchicine.

Safety & Warnings

Common Side Effects

Colchicine, while effective, is associated with a range of dose-dependent and potentially severe adverse effects, primarily affecting the gastrointestinal, neuromuscular, and hematologic systems.
Common gastrointestinal side effects include nausea, vomiting, diarrhea, and abdominal pain, which can be dose-limiting and often necessitate discontinuation of therapy.
These symptoms typically manifest rapidly due to the drug's impact on rapidly dividing cells in the GI tract.
More serious, albeit less frequent, adverse effects include myopathy and rhabdomyolysis, characterized by muscle pain, weakness, and elevated creatine kinase levels, with an increased risk in patients with renal or hepatic impairment, elderly individuals, or those concurrently taking statins or other drugs affecting colchicine metabolism.
Peripheral neuropathy, manifesting as numbness, tingling, or weakness in extremities, has also been reported.
Hematologic toxicities, such as myelosuppression (e.
g.
, agranulocytosis, aplastic anemia, neutropenia, thrombocytopenia), are rare but severe and warrant immediate cessation of the drug and complete blood count monitoring.
Other potential side effects include alopecia and elevated liver enzymes.
Patients should be counselled to report any unusual symptoms promptly to their healthcare provider.

Serious Warnings

Black Box Warning: **WARNING: FATAL TOXICITY WHEN CO-ADMINISTERED WITH STRONG CYP3A4 INHIBITORS OR P-GP INHIBITORS IN THE PRESENCE OF RENAL OR HEPATIC IMPAIRMENT.** The co-administration of colchicine with strong cytochrome P450 3A4 (CYP3A4) inhibitors or P-glycoprotein (P-gp) inhibitors is strictly contraindicated in patients with pre-existing renal or hepatic impairment. This critical interaction leads to a profound increase in systemic colchicine exposure, resulting in life-threatening or fatal toxicity. Colchicine is a substrate of both CYP3A4 and P-gp, and inhibition of these enzymes significantly impairs its metabolism and efflux, causing dangerously elevated plasma concentrations. Examples of strong CYP3A4 inhibitors include, but are not limited to, clarithromycin, ketoconazole, itraconazole, telithromycin, and nelfinavir. Examples of strong P-gp inhibitors include cyclosporine, ranolazine, and verapamil. Patients with compromised kidney or liver function are particularly vulnerable because their ability to excrete colchicine is already diminished. Therefore, combining these agents with colchicine in this high-risk patient population can rapidly lead to severe adverse events, including profound myelosuppression, potentially fatal gastrointestinal toxicity, myopathy, rhabdomyolysis, and peripheral neuropathy. Healthcare providers must meticulously review all concomitant medications, including over-the-counter drugs and herbal supplements, and assess renal and hepatic function prior to initiating colchicine therapy and throughout treatment to prevent these severe, often irreversible, consequences. This interaction is not simply a risk but a contraindication in this specific patient group.
Colchicine carries significant warnings that necessitate careful patient selection, monitoring, and medication review to prevent severe adverse outcomes.
A paramount concern involves drug-drug interactions, particularly with strong and moderate inhibitors of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp), as these interactions can profoundly increase colchicine plasma concentrations, leading to life-threatening or fatal toxicity.
Examples of such inhibitors include clarithromycin, itraconazole, cyclosporine, and certain protease inhibitors.
Patients with pre-existing renal or hepatic impairment are at substantially elevated risk of colchicine toxicity due to reduced drug clearance, even at standard doses.
Therefore, appropriate dose adjustments or avoidance are critical based on the degree of organ dysfunction.
Elderly patients are also more susceptible to adverse effects due to age-related physiological changes affecting drug metabolism and excretion.
Colchicine can cause blood dyscrasias, including myelosuppression, thus requiring monitoring of complete blood counts in patients on long-term therapy or those developing suggestive symptoms.
Neuromuscular toxicity, such as myopathy and rhabdomyolysis, can occur, especially in those with renal impairment or concurrent use of drugs like statins, necessitating prompt evaluation of muscle pain or weakness.
The drug is classified as Pregnancy Category C, and caution is advised during breastfeeding as it is excreted in breast milk.
Patients must be thoroughly educated on potential adverse effects and the importance of disclosing all concomitant medications, including over-the-counter drugs and herbal supplements.

How it Works (Mechanism of Action)

Colchicine exerts its therapeutic effects primarily through its anti-inflammatory properties, which are distinct from traditional analgesics and non-steroidal anti-inflammatory drugs (NSAIDs). At a molecular level, colchicine binds to tubulin, a protein critical for the formation of microtubules. This binding activity inhibits the polymerization of tubulin into microtubules, thereby disrupting various cellular functions that depend on an intact microtubule cytoskeleton. In the context of inflammatory conditions such as gout and Familial Mediterranean Fever (FMF), this disruption has several key consequences. Firstly, it impairs neutrophil chemotaxis and migration to sites of inflammation, such as joints affected by uric acid crystals in gout. Secondly, it inhibits the phagocytosis of urate crystals by neutrophils and macrophages, a pivotal step in the inflammatory cascade of acute gout. Thirdly, colchicine interferes with the assembly of the inflammasome, particularly the NLRP3 inflammasome, which is responsible for the activation and release of pro-inflammatory cytokines like interleukin-1 beta (IL-1β) and IL-6. By reducing the production and secretion of these potent inflammatory mediators, colchicine effectively attenuates the inflammatory response, thus providing symptomatic relief in acute gout flares and preventing recurrent attacks in both gout and FMF. Its anti-mitotic effects are also relevant at higher doses, contributing to potential adverse effects on rapidly dividing cells.

Commercial Brands (Alternatives)

No other brands found for this formula.